As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...

BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

Founded in 2012, 10x Genomics (NASDAQ:TXG ... revenue by selling their instruments and also consumables alongside the software. Its Chromium platform allows for single-cell analysis, while ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which enables high-throughput single cell gene expression profiling, 10X Genomics Xenium platform, and the ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

EDT Cathie Wood’s ARK Investment buys 191.5K shares of 10x Genomics (TXG) todayStay Ahead of the Market: Discover outperforming stocks ...